Open AccessASSESSMENT OF LIFE QUALITY IN PATIENTS WITH STAGE IIB-IIIB SQUAMOUS CELL CERVICAL CANCER RECEIVING PACLITAXEL CISPLATIN CHEMOTHERAPY REGIMEN BY EORTC QLQ-C30 QUESTIONNAIRE IN SANGLAH HOSPITAL DENPASAR
Author(s) -
Rini Noviyani,
Putu Ayu Indrayathi,
I Nyoman Gede Budiana,
Ketut Suwiyoga,
K. Tunas
Publication year - 2017
Publication title -
international journal of pharmacy and pharmaceutical sciences/international journal of pharmacy and pharmaceutical sciences
Language(s) - English
Resource type - Journals
eISSN - 2656-0097
pISSN - 0975-1491
DOI - 10.22159/ijpps.2017v9i5.17621
Subject(s) - medicine , cervical cancer , chemotherapy , regimen , cisplatin , paclitaxel , oncology , cancer , chemotherapy regimen , taxane , quality of life (healthcare) , gynecology , breast cancer , nursing
Objective: Cervical cancer was the prominent cause of women's death in developing states. Decrease in life quality was often encountered by patients with cervical cancer in advanced stages. One treatment method of cervical cancer at Sanglah Hospital was using paclitaxel cisplatin chemotherapy. Information on cervical cancer patient's life quality who received paclitaxel cisplatin chemotherapy was still limited, so research was required to observe cervical cancer patients’ life quality before the first and after the sixth paclitaxel cisplatin chemotherapy regimen.Methods: Observational study with prospective case study design was undertaken at the Polyclinic of Obstetrics and Gynecology Sanglah Hospital from January to August 2016. Sampling was conducted before chemotherapy I and after chemotherapy VI using consecutive sampling method. The EORTC QLQ C30 questionnaires were completed by the patients before chemotherapy I and after chemotherapy VI. Patients' life quality who had received paclitaxel cisplatin chemotherapy were assessed with 15 domains in EORTC QLQ C30 questionnaire. The data obtained were processed with STATA® version 14 and analysed using paired t test and Wilcoxon test with a confidence level of 95%.Results: The number of samples used in this study was 7 patients who received paclitaxel cisplatin chemotherapy. The results of the analysis showed that there were differences in cervical cancer patients’ life quality who had received paclitaxel cisplatin regimen chemotherapy before chemotherapy I and after chemotherapy VI with the result of p-value is 0.0005.Conclusion: There was a significant decrease in the value of cervical cancer patients' life quality who received paclitaxel cisplatin chemotherapy before chemotherapy I and after chemotherapy VI.